Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

BeOne Medicines (BEIGF) Gross Profit (2017 - 2025)

BeOne Medicines (BEIGF) has disclosed Gross Profit for 9 consecutive years, with $1.4 billion as the latest value for Q4 2025.

  • Quarterly Gross Profit rose 40.16% to $1.4 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.7 billion through Dec 2025, up 45.34% year-over-year, with the annual reading at $4.7 billion for FY2025, 45.34% up from the prior year.
  • Gross Profit for Q4 2025 was $1.4 billion at BeOne Medicines, up from $1.2 billion in the prior quarter.
  • The five-year high for Gross Profit was $1.4 billion in Q4 2025, with the low at $113.7 million in Q2 2021.
  • Average Gross Profit over 5 years is $605.5 million, with a median of $550.9 million recorded in 2021.
  • The sharpest move saw Gross Profit skyrocketed 1411.97% in 2021, then crashed 57.89% in 2022.
  • Over 5 years, Gross Profit stood at $165.4 million in 2021, then soared by 85.31% to $306.6 million in 2022, then surged by 72.41% to $528.6 million in 2023, then soared by 82.99% to $967.3 million in 2024, then skyrocketed by 40.16% to $1.4 billion in 2025.
  • According to Business Quant data, Gross Profit over the past three periods came in at $1.4 billion, $1.2 billion, and $1.2 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.